Pangea Bio

Drug Discovery · Kent, United Kingdom · Founded 2021 · Privately Held (backing)

Developer of a novel medicines platform designed to treat neurological disorders. Pangea Bio is based in Kent, United Kingdom and was founded in 2021. It was valued at $80 million at its early-stage round in Oct 2024, the last priced event on record. It has raised $21.7 million across 1 recorded round; the latest was a $15.6 million Series A in Oct 2023.

PMV mark · valuation
$80.0M
Oct 2026
Priced at
its early-stage round
Oct 2024
Total raised
$21.7M
Last round
Early Stage VC (Series A)
Oct 2023
What is Pangea Bio worth?
$80.0MPrivateMarketView mark · Oct 2026

Valued at $80.0M at its early-stage round, Oct 2024. Nothing has traded since.

Free account
More of Pangea Bio with a free account
  • ·The complete investor list: 19 names
  • ·Watch Pangea Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Pangea Bio funding history

1 rounds
DateRoundRaisedPost-money
Oct 2023Early Stage VC (Series A)$15.6M▮
Unlock post-money valuations

Membership and data by Private Market View

Pangea Bio valuation

Pangea Bio was valued at $80 million at its early-stage round in Oct 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Pangea Bio raised?

Pangea Bio has raised $21.7 million in total; 1 of its rounds is on record. The largest on record was a $15.6 million Series A in Oct 2023.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Hyku Biosciences ($85 million), Linnaeus Therapeutics ($83.1 million) and Parallel Bio ($71.5 million).

How Pangea Bio's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Pangea Bio, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Pangea Bio

What is Pangea Bio worth?
Pangea Bio is valued at $80.0M as of Oct 2026. Valued at $80.0M at its early-stage round, Oct 2024. Nothing has traded since.
How much has Pangea Bio raised?
Pangea Bio has raised $21.7M in total funding across 1 recorded rounds.
When did Pangea Bio last raise?
Pangea Bio last raised in Oct 2023 (Early Stage VC (Series A)), raising $15.6M.